| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $30,389,573 | 19 | 100 |
Sells | $0 | 0 | 0 |
| STAHLBERG JAN | 10 percent owner | 17 | $18.99M | 0 | $0 | $18.99M |
| Von Koch Thomas | 10 percent owner | 1 | $10M | 0 | $0 | $10M |
| JACINTO RICHARD II | 10 percent owner | 1 | $1.4M | 0 | $0 | $1.4M |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $30.39M and sold $0 worth of DiaMedica Therapeutics Inc. stock.
On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $9.46M and sold $3.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: STAHLBERG JAN (10 percent owner) — $18.99M. Von Koch Thomas (10 percent owner) — $10M. JACINTO RICHARD II (10 percent owner) — $1.4M.
The last purchase of 73,099 shares for transaction amount of $626,817 was made by STAHLBERG JAN (10 percent owner) on 2025‑11‑25.
| 2025-11-25 | STAHLBERG JAN | 10 percent owner | 73,099 0.1577% | $8.57 | $626,817 | -6.53% | ||
| 2025-11-24 | STAHLBERG JAN | 10 percent owner | 40,253 0.08% | $7.89 | $317,721 | +5.69% | ||
| 2025-11-21 | STAHLBERG JAN | 10 percent owner | 208,872 0.3895% | $7.41 | $1.55M | +10.62% | ||
| 2025-11-20 | STAHLBERG JAN | 10 percent owner | 128,426 0.253% | $7.41 | $951,213 | +16.27% | ||
| 2025-11-19 | STAHLBERG JAN | 10 percent owner | 240,352 0.4557% | $7.21 | $1.73M | +14.38% | ||
| 2025-11-18 | STAHLBERG JAN | 10 percent owner | 182,882 0.3436% | $6.75 | $1.23M | +21.01% | ||
| 2025-11-17 | STAHLBERG JAN | 10 percent owner | 187,393 0.3658% | $6.52 | $1.22M | +30.27% | ||
| 2025-08-27 | STAHLBERG JAN | 10 percent owner | 50,772 0.0986% | $6.00 | $304,632 | +17.64% | ||
| 2025-08-26 | STAHLBERG JAN | 10 percent owner | 59,648 0.1133% | $6.00 | $357,888 | +16.03% | ||
| 2025-08-25 | STAHLBERG JAN | 10 percent owner | 338,265 0.6425% | $6.00 | $2.03M | +16.92% | ||
| 2025-08-22 | STAHLBERG JAN | 10 percent owner | 59,788 0.1129% | $5.96 | $356,576 | +14.73% | ||
| 2025-08-21 | STAHLBERG JAN | 10 percent owner | 48,172 0.0936% | $5.96 | $287,028 | +18.13% | ||
| 2025-08-20 | STAHLBERG JAN | 10 percent owner | 71,107 0.1343% | $5.86 | $416,495 | +16.67% | ||
| 2025-08-15 | STAHLBERG JAN | 10 percent owner | 8,233 0.0158% | $6.00 | $49,398 | +15.92% | ||
| 2025-08-14 | STAHLBERG JAN | 10 percent owner | 70,414 0.1358% | $5.99 | $421,921 | +16.14% | ||
| 2025-08-13 | STAHLBERG JAN | 10 percent owner | 293,601 0.5594% | $5.91 | $1.73M | +16.25% | ||
| 2025-07-23 | Von Koch Thomas | 10 percent owner | 2.86M 4.528% | $3.50 | $10M | +33.59% | ||
| 2025-07-23 | STAHLBERG JAN | 10 percent owner | 1.54M 2.4451% | $3.50 | $5.4M | +33.59% | ||
| 2025-07-23 | JACINTO RICHARD II | 10 percent owner | 400,000 0.6339% | $3.50 | $1.4M | +33.59% | ||
| 2024-06-28 | Von Koch Thomas | 10 percent owner | 1.2M 2.6697% | $2.50 | $3M | +42.37% |
| STAHLBERG JAN | 10 percent owner | 8825742 16.9473% | $66.85M | 18 | 0 | +42.37% |
| Von Koch Thomas | 10 percent owner | 8383577 16.0983% | $63.51M | 4 | 1 | +19.06% |
| JACINTO RICHARD II | 10 percent owner | 4958823 9.522% | $37.56M | 1 | 0 | |
| TomEnterprise AB | 2855827 5.4838% | $21.63M | 1 | 0 | +16.67% | |
| Wambeke David J. | Chief Business Officer | 527114 1.0122% | $3.99M | 3 | 0 | +24.24% |
| Giuffre Randall Michael | director | 360355 0.692% | $2.73M | 10 | 0 | +49.69% |
| Pilnik Richard D. | director | 248245 0.4767% | $1.88M | 7 | 0 | +16.82% |
| Pauls Dietrich John | President and CEO | 68591 0.1317% | $519,576.83 | 5 | 0 | +14.27% |
| Burroughs Amy L. | director | 44950 0.0863% | $340,496.25 | 1 | 0 | <0.0001% |
| ALCORN HARRY W JR | SVP, Clinical Operations | 43582 0.0837% | $330,133.65 | 5 | 0 | <0.0001% |
| Kellen Scott | CFO and Secretary | 32290 0.062% | $244,596.75 | 6 | 0 | +15.37% |
| Semba Charles Pauling | director | 29943 0.0575% | $226,818.23 | 1 | 0 | <0.0001% |
| Xiao Zhenyu | 7100 0.0136% | $53,782.50 | 1 | 0 | <0.0001% | |
| Parsons James T. | director | 6100 0.0117% | $46,207.50 | 1 | 0 | <0.0001% |
| Verdoorn Todd A. | Chief Scientific Officer | 2000 0.0038% | $15,150.00 | 1 | 0 | <0.0001% |
$5,911,307 | 70 | -1.38% | $404.4M | |
$54,836,085 | 68 | -0.52% | $393.86M | |
DiaMedica Therapeutics Inc. (DMAC) | $17,468,215 | 46 | 18.85% | $394.49M |
$130,095 | 43 | 45.19% | $447.63M | |
$24,384,691 | 42 | -30.27% | $374.21M | |
$74,231,875 | 30 | 40.62% | $420.41M | |
$54,828,550 | 26 | -13.88% | $360.9M | |
$4,306,464 | 21 | 37.34% | $406.02M | |
$104,137,421 | 15 | 21.28% | $393.93M | |
$57,263,116 | 11 | -8.37% | $366.31M | |
$112,952,085 | 11 | -19.19% | $451.07M | |
$14,995,689 | 8 | 3.76% | $441.45M | |
$603,645 | 8 | 57.40% | $418.27M | |
$43,326,461 | 6 | 16.01% | $357.49M | |
$79,246,559 | 5 | -27.73% | $426.17M | |
$88,549,962 | 5 | -16.91% | $352.6M | |
$4,888,000 | 3 | -20.50% | $352.66M | |
$2,857,000 | 2 | -5.23% | $418.28M | |
$20,020,000 | 1 | -75.24% | $366.1M |
| Increased Positions | 54 | +125.58% | 5M | +58.66% |
| Decreased Positions | 15 | -34.88% | 1M | -13.26% |
| New Positions | 23 | New | 2M | New |
| Sold Out Positions | 4 | Sold Out | 89,961 | Sold Out |
| Total Postitions | 82 | +90.7% | 13M | +45.4% |
| Omega Advisors Inc. | $25,929.00 | 6.29% | 3.27M | +2M | +98.17% | 2025-09-30 |
| Blackrock, Inc. | $13,308.00 | 3.23% | 1.68M | +486,326 | +40.81% | 2025-09-30 |
| Millennium Management Llc | $9,415.00 | 2.28% | 1.19M | +1M | New | 2025-09-30 |
| Paragon Associates & Paragon Associates Ii Joint Venture | $6,939.00 | 1.68% | 875,000 | +225,000 | +34.62% | 2025-09-30 |
| Geode Capital Management, Llc | $5,645.00 | 1.37% | 711,818 | +81,670 | +12.96% | 2025-09-30 |
| Vanguard Group Inc | $5,270.00 | 1.28% | 664,575 | -870,479 | -56.71% | 2025-09-30 |
| Morgan Stanley | $4,596.00 | 1.12% | 579,585 | +339,109 | +141.02% | 2025-09-30 |
| First Manhattan Co. Llc. | $4,005.00 | 0.97% | 505,000 | -101,435 | -16.73% | 2025-09-30 |
| State Street Corp | $3,779.00 | 0.92% | 476,583 | +224,635 | +89.16% | 2025-09-30 |
| Bleichroeder Lp | $3,032.00 | 0.74% | 382,317 | 0 | 0% | 2025-09-30 |